Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study
暂无分享,去创建一个
T. Barbui | S. Schnittger | P. Guglielmelli | A. Pancrazzi | A. Vannucchi | A. Bench | E. Lippert | S. Hermouet | A. Jones | H. Pahl | N. Cross | S. Akiki | D. Grimwade | M. McMullin | C. Harrison | J. Prchal | D. Mclornan | T. Kelley | K. Tobal | B. V. D. Reijden | J. Jansen | B. A. van der Reijden | C. Chomienne | M. Percy | B. Wilkins | S. Schwemmers | T. Alpermann | J. Jovanovic | J. Kiladjian | B. Cassinat | N. Pallisgaard | N. Maroc | A. Ivey | E. Oppliger Leibundgut | G. Nickless | K. Cuthill | K. Yeoman | J. Bryon | S. Jeffries | A. Jones | A. Gruender | S. Reading | E. O. Leibundgut | Jacques Kiladjian | Albert Gruender | Adam Ivey